Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. KESIMPTA (ofatumumab)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

KESIMPTA (ofatumumab)

Medicine - Posted on Jun 12 2025
Active substance (DCI)
  • ofatumumab
history (3)
  • 5/14/25

    KESIMPTA (ofatumumab) - Sclérose en plaques

    Réévaluation à la demande de la CT L'essentiel Avis favorable au maintien du remboursement dans le traitement des patients a...
    CAV :
    54321
    icône flèche
  • 1/18/23

    KESIMPTA (ofatumumab) - Sclérose en plaques

    Réévaluation. Recommandations particulières Compte tenu de la complexité de la prise en charge des SEP-R très actives, dans ...
    icône flèche
  • Economic analysis
    6/2/21

    KESIMPTA (ofatumumab)

    Key points Favourable opinion for reimbursement in the treatment of adult patients with relapsing forms of multiple sclerosi...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • L04AG12
Manufacturer
NOVARTIS PHARMA
Presentation

KESIMPTA 20 mg, solution injectable en seringue préremplie
1 seringue préremplie en verre de 0,4 mL (CIP : 34009 302 268 5 8)

KESIMPTA 20 mg, solution injectable en stylo prérempli
1 stylo prérempli en verre de 0,4 mL (CIP : 34009 302 269 7 1)

All our publications
    Autoimmune diseases Central nervous system diseases Demyelinating diseases Drug therapy

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
DAjF2NkHMmFMXZmk